Koers Jaguar Health Inc Nasdaq
Aandelen
US47008L1061
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 15,11 mln. 14 mln. | Omzet 2025 * | 22,66 mln. 21 mln. | Marktkapitalisatie | 21,32 mln. 19,76 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -26 mln. -24,1 mln. | Nettowinst (verlies) 2025 * | -21 mln. -19,46 mln. | EV/omzet 2024 * | 1,41 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,94 x |
K/w-verhouding 2024 * |
-0,81
x | K/w-verhouding 2025 * |
-1,04
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,62% |
Recentste transcriptie over Jaguar Health Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Lisa Conte
FOU | Founder | 65 | 06-06-13 |
Carol Lizak
DFI | Director of Finance/CFO | 60 | 01-05-19 |
Chief Tech/Sci/R&D Officer | 60 | 01-05-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Lisa Conte
FOU | Founder | 65 | 06-06-13 |
James Bochnowski
CHM | Chairman | 80 | 01-02-14 |
John Micek
BRD | Director/Board Member | 71 | 01-04-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,38% | 114 mld. | |
+10,13% | 104 mld. | |
-11,69% | 22,5 mld. | |
+2,21% | 22,57 mld. | |
-10,88% | 17,95 mld. | |
-41,90% | 16,48 mld. | |
-16,00% | 15,82 mld. | |
+2,28% | 13,55 mld. | |
+20,54% | 10,99 mld. |